Claims for Patent: 11,850,248

Summary for Patent: 11,850,248

Title:	Therapies with 3rd generation EGFR tyrosine kinase inhibitors
Abstract:	The present invention relates to therapies with 3rd generation EGFR tyrosine kinase inhibitors. Embodiments of the invention relate to the administration of lazertinib to patients diagnosed with non-small cell lung cancer (NSCLC).
Inventor(s):	Seonmi Kang, SeWoong Oh
Assignee:	Yuhan Corp
Application Number:	US15/931,626
Patent Claims:	1. A method of treating cancer in a human subject comprising administering lazertinib to the subject in an amount between about 20 mg and about 320 mg once daily, wherein the cancer is EGFR Mutation Positive non-small cell lung cancer (NSCLC). 2. The method of claim 1, wherein the cancer is EGFR T790M+ NSCLC. 3. The method of claim 1, wherein the subject exhibits brain metastasis. 4. The method of claim 1 comprising administering the lazertinib to the subject in an amount between about 40 mg and about 240 mg once daily. 5. The method of claim 1 comprising administering the lazertinib to the subject in an amount of about 240 mg once daily. 6. The method of claim 1 comprising administering the lazertinib to the subject once daily over a period of at least 3 weeks. 7. The method of claim 1 comprising administering the lazertinib to the subject once daily over a period of at least 6 weeks.